Current issues in the enzymology of mitomycin C metabolic activation

General Pharmacology

Volumn 31, Issue 4, 1998, Pages 539-544

  Spanswick, V J ^a   Cummings, J ^a   Smyth, J F ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

DT diaphorase; Metabolism; Mitomycin C

Indexed keywords

MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

CYTOTOXICITY; DRUG ACTIVITY; DRUG METABOLISM; HUMAN; HYPOXIA; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; ENZYMES; HUMANS; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NUCLEIC ACID SYNTHESIS INHIBITORS; PRODRUGS;

EID: 0032190499     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00055-X     Document Type: Review

References (57)

1. Adams G.E., Stratford I.J. Bioreductive drugs for cancer therapy. the search for tumour specificity Int. J. Radiat. Oncol. Biol. Phys. 29:1994;231-238.
2. Beall H.D., Mulcahy R.T., Siegel D., Traver R.D., Gibson N.W., Ross D. Metabolism of bioreductive antitumour compounds by purified rat and human DT-diaphorases. Cancer Res. 54:1994;3196-3201.
3. Begleiter A., Leith M., McClarty G., Bennken S., Goldberg G.S., Wright J.A. Characterisation of L5178Y murine lymphoblasts resistant to quinone antitumour agents. Cancer Res. 48:1988;1727-1735.
4. Belcourt M.F., Hodnick W.F., Rockwell S., Sartorelli A.C. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc. Natl. Acad. Sci. USA. 93:1996;456-460. a.
5. Belcourt M.F., Hodnick W.F., Rockwell S., Sartorelli A.C. Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem. Pharmac. 51:1996;1669-1678. b.
6. Bush R.S., Jenkins R.D.T., Allt W.E.C., Beale F.A., Bean H., Dembo A.J., Pringle J.F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer. 37:1978;302-306.
7. Butler J., Hoey B.M. Are reduced quinones necessarily involved in the antitumour activity of quinone drugs? Br. J Cancer. 55:1987;53-59.
8. Chirrey L., Cummings J., Halbert G.W., Smyth J.F. Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tissue in vivo. Cancer Chemother. Pharmac. 35:1995;318-322.
9. Cummings J., Allan L., Smyth J.F. Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. implications for the drugs in vivo mechanism of action Biochem. Pharmac. 47:1994;1345-1356.
10. Cummings J., Spanswick V.J., Smyth J.F. Re-evaluation of the molecular pharmacology of mitomycin C. Eur. J. Cancer. 31A:1995;1928-1933.
11. Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria I. anthracycline radical formation by NADH-dehydrogenase J. Biol. Chem. 261:1986;3060-3067.
12. Doroshow J.H. Reductase activation of mitomycin C. a delicate balance J. Natl. Cancer Inst. 84:1992;1138-1139.
13. Fitzsimmons S.A., Workman P., Grever M., Paull K., Camalier R., Lewis A.D. Reductase enzyme expression across the National Cancer Institute tumor cell line panel. correlation with sensitivity to mitomycin C and EO9 J. Natl. Cancer Inst. 88:1996;259-269.
14. Forrest G.L., Akman S., Doroshow J., Rivera H., Kaplan W.D. Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity. Mol. Pharmac. 40:1991;502-507.
15. Forrest G.L., Sapra A., Gonzales B., Rivera H., Yam B., Kaplan W.D. Cloning and expression of rabbit liver carbonyl reductase with quinone reductase and aldoketo reductase (daunorubicin reductase) activity. FASEB J. 8:1994;1465.
16. Gerweck L.E., Rhee J.G., Koutcher J.A., Song C.W., Urano M. Regulation of pH in murine tumours and muscle. Radiat. Res. 126:1991;206-209.
17. Gustafson D.L., Pritsos C.A. Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and anaerobic conditions. Cancer Res. 53:1993;5470-5474.
18. Hiraoka M.A., Hahn G.M. Comparison between tumour pH and cell sensitivity to heat in RIF-1 tumours. Cancer Res. 49:1989;3734-3735.
19. 5 reductase. Cancer Res. 53:1993;4907-4912.
20. Hoey B.M., Butler J., Swallow A.J. Reductive activation of mitomycin C. Biochemistry. 27:1988;2608-2614.
21. Jarabak J. Polycyclic aromatic hydrocarbon quinone-mediated oxidation reduction cycling catalysed by a human placental NADPH-linked carbonyl reductase. Arch. Biochem. Biophys. 291:1991;334-338.
22. Joseph P., Xu Y., Jaiswal A.K. Non-enzymatic and enzymatic activation of mitomycin C. identification of a unique cytosolic activity Int. J. Cancer. 65:1996;263-271.
23. Kennedy K.A., Sliger S.G., Polomski L., Sartorelli A.C. Metabolic activation of mitomycin C by liver microsomes and nuclei. Biochem. Pharmac. 31:1982;2011-2016.
24. Keyes S.R., Francasso P.M., Heimbrook D.C., Rockwell S., Sliger S.G., Sartorelli A.C. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res. 44:1984;5638-5643.
25. Lind C., Hochstein P., Ernster L. DT-diaphorase as a quinone reductase. a cellular control device against semiquinone and superoxide radical formation Arch. Biochem. Biophys. 216:1982;178-185.
26. Marshall R.S., Paterson M.C., Rauth A.M. Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual. Biochem. Pharmac. 41:1991;1351-1360.
27. Moulder J.E., Rockwell S. Hypoxic fractions in solid tumours. Int. J. Radiat. Oncol. Biol. Phys. 10:1984;695-712.
28. Newell K.W., Wood P., Stratford I., Tannock I. Effects of agents which inhibit the regulation of intracellular pH on murine solid tumour. Br. J. Cancer. 66:1992;311-317.
29. Oostveen E.A., Speckamp W.N. Mitomycin C analogues 1. indoloquinones as (potential) bisalkylating agents Tetrahedron. 43:1987;255-262.
30. Overgaard J. Importance of tissue hypoxia in radiotherapy. a meta-analysis of controlled clinical trials Radiother. Oncol. 24:1992;64.
31. Pan S.S., Andrews P.A., Glover C.J., Bachur N.R. Reductive activation of mitomycin C and mitomycin C metabolites by NADPH:cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem. 259:1984;959-966.
32. Parkins C.S., Denekamp J.D., Chaplin D.J. Enhancement of mitomycin C cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res. 13:1993;1437-1442.
33. Peterson D.W., Fischer J. Autocatalytic quinone methide formation of mitomycin. C. Biochemistry. 25:1986;4077-4084.
34. Plumb J.A., Workman P. Unusually marked hypoxia sensitisation to indoloquinone EO9 and mitomycin C in a human colon tumour cell line that lacks DT-diaphorase. Int. J. Cancer. 56:1994;134-139.
35. Plumb J.A., Gerritsen M., Workman P. DT-diaphorase protects cells from hypoxic cytotoxicity of indoloquinone EO9. Br. J. Cancer. 70:1994;1136-1143.
36. Powis G. Metabolism and reactions of quinoid anticancer agents. Pharmac. Ther. 35:1987;57-162.
37. Pritsos C.A., Sartorelli A.C. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res. 46:1986;3528-3532.
38. Pritsos C.A. Re; Reductase enzyme expression across the National Cancer Institute tumor cell line panel. correlation with sensitivity to mitomycin C and EO9 J. Natl. Cancer Inst. 88:1996;1161-1163.
39. Pritsos C.A., Vimalachandra B. Mitochondrial dysfunction and ATP depletion in mitomycin C treated mice. Proc. Am. Assoc. Cancer Res. USA. 36:1995;352.
40. Ross D., Siegel D., Beall H., Prakash A.S., Mulcahy R.T., Gibson N.W. DT-diaphorase in activation and detoxification of quinones. bioreductive activation of mitomycin C Cancer Metastasis Rev. 12:1993;83-101.
41. Saunders M., Jaffar M., Patterson A.V., Naylor M., Adams G.E., Harris A., Stratford I.J. Structural requirements for EO9 toxicity and dependence on P-450 reductase for activation. Br. J. Cancer. 73:1996;27.
42. 4 for the reductive activation of mitomycin C. J. Am. Chem. Soc. 115:1993;10497-10509.
43. Schlager J.J., Powis G. NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumour tissue. effects of smoking and alcohol Int. J. Cancer. 45:1990;403-409.
44. Siegel D., Gibson N.W., Preusch P.C., Ross D. Metabolism of mitomycin C by DT-diaphorase. role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells Cancer Res. 50:1990;7483-7489.
45. Siegel D., Beall H., Senekowitsch C., Kasai M., Arai H., Gibson N.W., Ross D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry. 31:1992;7879-7885.
46. Spanswick V.J., Cummings J., Ritchie A.A., Smyth J.F. Identification of new mitomycin C metabolising enzymes in tumour tissue. Br. J. Cancer. 71:1995;39.
47. Spanswick V.J., Cummings J., Smyth J.F. Enzymology of mitomycin C metabolic activation in tumour tissue. characterisation of a novel mitochondrial reductase Biochem. Pharmac. 51:1996;1623-1630.
48. Tannock I.F., Rotin D. Acid pH in tumours and its potential for therapeutic exploitation. Cancer Res. 49:1989;4373-4383.
49. Thornally P.J., Bannister W.H., Bannister V.J. Reduction of oxygen by NADH/NADH:dehydrogenase in the presence of adriamycin. Free Radical Res. Commun. 2:1986;163-171.
50. Tomasz M., Lipman R. Reductive metabolism and alkylating activity of mitomycin C induced by rat liver microsomes. Biochemistry. 20:1981;5056-5061.
51. Walton M.I., Bibby M.C., Double J.A., Plumb J.A., Workman P. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur. J. Cancer. 28A:1992;1597-1600.
52. Watanabe F., Nakano Y., Tachikake N., Tamura Y., Yamanaka H., Kitaoka S. Occurrence and tissue distribution of both NADH- and NADPH-linked aquacobalamin reductases in some vertabrates. J. Nutr. Sci. Vitaminology. 36:1990;349-356.
53. Watanabe F., Nakano Y., Saido H., Tamura Y., Yamanaka H. NADPH-cytochrome c (P-450) reductase has the activity of NADPH-linked aquacobalamin reductase in rat liver microsomes. Biochim. Biophys. Acta. 119:1992;175-177.
54. Wermuch B., Platts K.L., Siedel A., Oesch F. Carbonyl reductase provides the enzymatic basis of quinone detoxification in man. Biochem. Pharmac. 35:1986;1277-1282.
55. Wilson W.R., Moselen J.W., Cliffe S., Denny W.A., Ware D.C. Exploiting tumour hypoxia through bioreductive release of diffusible cytotoxins. the cobalt (III)-nitrogen mustard complex SN24771 Int. J. Radiat. Oncol. Biol. Phys. 29:1994;323-327.
56. Workman P. and Walton M. I. (1990) Enzyme-directed bioreductive drug development. In Selective Activation of Drugs by Redox Processes. (Edited by Adams G. E., Breccia A., Fielden E. M. and Wardman P.) pp. 173-191. Plenum Press, New York.
57. Workman P., Walton M.I., Powis G., Schlager J.J. DT-diaphorase, questionable role in mitomycin C resistance but a target for novel bioreductive drugs? Br. J. Cancer. 60:1989;800-802.